Angle, the Surrey-based technology investment firm, has seen its share price rocket nearly 15% on news one of its divisions has found a new way to detect prostate cancer.
Parsortix, which is 90% owned by Angle, claims its "separation technology" can capture prostate cancer cells added to blood.
The will allow for the early detection of cancer and the monitoring of patients both during and after treatment.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Angle Founder and Chief Executive, Andrew Newland, commented: "The successful capture and identification of prostate cancer cells added to blood further substantiates the potential for the Parsortix separation technology to become a market-leading product, which is simple, effective and affordable."
At 09:45, Angle shares were trading at 89.5p, up 14.5% (10.51p).
BS
-
Halifax: UK house prices approach 2022 peak but costs remain high for buyers ahead of Autumn BudgetNews Average house prices rose for the third consecutive month during September - is now a good time to buy a property?
-
Six months left to give your state pension an extra boost – should you buy national insurance credits?News Older workers have until 5 April 2025 to make a backdated claim for NI credits to 2006/2007 that could boost their state pension income
